KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 252.7%.

  • Novavax's EBIT Margin fell 941300.0% to 252.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.74%, marking a year-over-year increase of 647900.0%. This contributed to the annual value of 36.49% for FY2024, which is 211000.0% up from last year.
  • Latest data reveals that Novavax reported EBIT Margin of 252.7% as of Q3 2025, which was down 941300.0% from 57.75% recorded in Q2 2025.
  • Novavax's EBIT Margin's 5-year high stood at 77.33% during Q1 2025, with a 5-year trough of 386.37% in Q1 2023.
  • Over the past 5 years, Novavax's median EBIT Margin value was 68.24% (recorded in 2022), while the average stood at 108.68%.
  • As far as peak fluctuations go, Novavax's EBIT Margin skyrocketed by 6313800bps in 2021, and later tumbled by -4161000bps in 2023.
  • Quarter analysis of 5 years shows Novavax's EBIT Margin stood at 371.27% in 2021, then skyrocketed by 82bps to 68.24% in 2022, then rose by 8bps to 63.01% in 2023, then plummeted by -136bps to 148.43% in 2024, then plummeted by -70bps to 252.7% in 2025.
  • Its EBIT Margin stands at 252.7% for Q3 2025, versus 57.75% for Q2 2025 and 77.33% for Q1 2025.